Inovio to develop COVID-19 DNA-encoded monoclonal antibodies

By The Science Advisory Board staff writers

December 15, 2020 -- Inovio, along with a team of scientists from the Wistar Institute, AstraZeneca, the University of Pennsylvania, and Indiana University, has received a $37.6 million grant from the Defense Advanced Research Projects Agency, a branch of the U.S. Department of Defense, to develop COVID-19 treatments.

The grant is for the use of Inovio's DNA-encoded monoclonal antibody (dMAb) technology to develop anti-SARS-CoV-2-specific dMAbs, which could function as both a therapeutic and preventive treatment for COVID-19.

The public-private partnership means Inovio can not only broaden the scope and application of its DNA medicines, but also open the door for better patient administration and more cost-effective, scalable production of monoclonal antibody products for other infectious diseases and cancers, the firm said.

Under the two-year grant, Inovio and Wistar will construct COVID-19 dMAb candidates mirroring AstraZeneca's traditional recombinant monoclonal antibody candidates that are currently being tested in clinical trials. The dMAb candidates can be developed and produced in vivo, which offers a cost-effective and scalable therapeutic option, the firm said.

Afterward, the dMAb candidates will be advanced into preclinical studies and then into first-in-human clinical trials within one year of funding.

Inovio expands COVID-19 vaccine manufacturing with Kaneka
Inovio has brought Belgium-based Kaneka Eurogentec on board a global consortium of companies that will be manufacturing its DNA COVID-19 vaccine INO-4800,...
Inovio begins late phase clinical trials for COVID-19 vaccine
Inovio has received clearance from the U.S. Food and Drug Administration (FDA) to proceed with the phase II segment of its phase II/III clinical trial...
Will mutation of the SARS-CoV-2 virus affect vaccine effectiveness?
What impact will mutation of the SARS-CoV-2 virus have on the effectiveness of COVID-19 vaccines that are in development? In a new study published in...
FDA halts Inovio COVID-19 vaccine trial
The U.S. Food and Drug Administration (FDA) has halted Inovio's clinical trial of its COVID-19 vaccine candidate, INO-4800.
Thermo Fisher to manufacture Inovio's COVID-19 vaccine
Thermo Fisher Scientific has signed a letter of intent to manufacture Inovio's DNA COVID-19 vaccine candidate, INO-4800.

Copyright © 2020 scienceboard.net


Conferences
HPLC 2022
June 18-23
San Diego, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter